Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Bufei Yishen granule
Henan University of Traditional Chinese Medicine
Chronic Obstructive Pulmonary Disease
1 trial -
Bupivacaine
United Therapeutics Europe Ltd
Postoperative Pain
1 trial -
Bupivacaine HCl
Pacira Ireland Limited
Hemorrhoids
1 trial -
Bupivacaine Liposome Injection
United Therapeutics Europe Ltd
Osteoarthritis
1 trial -
Buprenorphine
BRIGHT MINDS BIOSCIENCES INC.
Heroin Dependence
2 trials -
Buprenorphine +OTP
BRIGHT MINDS BIOSCIENCES INC.
Heroin Addiction
1 trial -
Buprenorphine/naloxone
BRIGHT MINDS BIOSCIENCES INC.
Heroin Dependence
2 trials -
Busulfan (BU)
The First People's Hospital of Lianyungang
Primary Central Nervous System Lymphoma
1 trial -
C1 esterase inhibitor [human] (C1INH-nf)
Takeda
Hereditary Angioedema
5 trials -
C1 esterase inhibitor [human] liquid
Takeda
Hereditary Angioedema (HAE)
1 trial -
CAPECITABINE, DS-8201a, INFLIXIMAB, CISPLATIN, MYCOPHENOLATE MOFETIL, CAPECITABINE, KEYTRUDA 25 mg/mL concentrate for solution for infusion, FLUOROURACIL, Rilvegostomig, OXALIPLATIN, TRASTUZUMAB
AstraZeneca AB
HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
1 trial -
CAPECITABINE, PACLITAXEL, CAPECITABINE, DS-8201a, Abraxane 5 mg/ml powder for dispersion for infusion.
AstraZeneca AB
HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed on Endocrine Therapy in the Metastatic Setting.
1 trial -
CARBOPLATIN , FLUOROURACIL , JNJ-61186372, CISPLATIN , PEMBROLIZUMAB
Janssen-Cilag International N.V.
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
1 trial -
CARBOPLATIN, CARBOPLATIN, DS-8201a, PEMETREXED, CISPLATIN, PEMBROLIZUMAB
Daiichi Sankyo
Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer
1 trial -
CARBOPLATIN, CARBOPLATIN, IPILIMUMAB, PEMETREXED, CISPLATIN, INFLIXIMAB, PEMETREXED, Mycofit, 250 mg, kapsułki twarde, NIVOLUMAB, volrustomig
AstraZeneca AB
Unresectable Pleural Mesothelioma
1 trial -
CARBOPLATIN, CISPLATIN, PEMBROLIZUMAB, PEMETREXED, DS-8201a, PEMETREXED
AstraZeneca AB
Unresectable, locally advanced, or metastatic Non-Small Cell Lung Cancer with HER2 exon 19 or 20 mutations
1 trial -
CARBOPLATIN, GEMCITABINE, PEMBROLIZUMAB, CISPLATIN, BT8009, AVELUMAB
BICYCLE THERAPEUTICS
Locally advanced or metastatic urothelial cancer
1 trial -
CARBOPLATIN, GEMCITABINE, PEMETREXED, Sindaxel 6 mg/ml concentrat pentru soluţie perfuzabilă, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CISPLATIN, Abraxane 5 mg/ml powder for dispersion for infusion., RO 749-9790/F02-02
Hoffmann-La Roche
RET fusion−positive, metastatic Non-Small Cell Lung Cancer
1 trial -
CASIMERSEN (SRP-4045), GOLODIRSEN (SRP-4053), 0,9% sodium chloride
Sarepta Therapeutics
Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping.
1 trial -
CBD 100 mg/mL Oral Solution
COGNITION THERAPEUTICS INC
Treatment Resistant Psychosis
1 trial -
CBD 100 mg/mL Oral Solution
COGNITION THERAPEUTICS INC
Psychosis
1 trial -
CEFTAZIDIME, PIPERACILLIN, CEFTAZIDIME AND BETA-LACTAMASE INHIBITOR , CEFTOLOZANE, CEFTAZIDIME, CEFEPIME , CEFEPIME, MEROPENEM , TAZOBACTAM, TAZOBACTAM, MEROPENEM, AMIKACIN , AMIKACIN, PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , CEFTOLOZANE AND BETA-LACTAMASE INHIBITOR , AVIBACTAM, CEFTAZIDIME
Pari Pharma GmbH
antibiotic therapy in Sepsis
1 trial -
CELLULOSE, MICROCRYSTALLINE, OSELTAMIVIR , DEXAMETHASONE
The George Institute
Severe Influenza
1 trial -
CEP-33457
Teva Pharma GmbH
Systemic Lupus Erythematosus
2 trials
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources